April 19, 2022 -- ScienceBoard.net recently caught up with NKILT Therapeutics leaders Raphael Ognar and Henri Bayle at the 2022 American Association for Cancer Research (AACR) Annual Meeting in New Orleans.
Since ScienceBoard first met with CEO and co-founder Raphael Ognar at the Society for Immunotherapy of Cancer's 2021 annual meeting last November, NKILT has moved from stealth mode into active fund seeking that will allow them to add to their leadership and lab teams and launch preclinical studies soon.
Ognar said the company has started to target and hire their science lab personnel and hopes to begin lab work in the coming weeks. NKILT has also filed several patents on its intellectual property to secure the uniqueness and specificity of their technology, which is based on the killer cell immunoglobulin-like receptors concept and the activation of the natural killer cell concept.
"We are growing, building, and ready to accelerate as soon as we increase our early funding," Ognar said.
Click on the video below to learn more.